Claims
- 1. A system for providing a therapeutic dose of bioactive agent for use in treating a patient, comprising:
a container; and a volume of material stored within the container in substantially sterile form; and wherein the material comprises a tachykinin or an analog or derivative thereof.
- 2. The system of claim 1, wherein the tachykinin or analog or derivative thereof comprises a sialokinin or an analog or derivative thereof.
- 3. The system of claim 2, wherein the sialokinin or analog or derivative thereof comprises SK1 or an analog or derivative thereof.
- 4. The system of claim 1, wherein the material comprises a combination of SK1 and SK2 sialokinins or analogs or derivatives thereof.
- 5. The system of claim 4, wherein the ratio of SK1 to SK2 sialokinins in the material is equal to about 4:1.
- 6. The system of claim 1, wherein:
the material comprises a carrier vehicle; and the tachykinin has between about 1 and about 10 nanomolar concentration in the carrier vehicle.
- 7. The system of claim 1, wherein:
the material comprises a carrier vehicle; and the carrier vehicle comprises a non-sialokinin protein.
- 8. The system of claim 1, wherein the tachykinin is naturally occurring.
- 9. The system of claim 1, wherein the tachykinin is synthesized.
- 10. The system of claim 1, wherein the container comprises a vial with a needle puncture valve adapted to allow needle filling of the vial contents.
- 11. A system for treating an abnormal cellular condition at a location within a body of a patient, comprising:
a delivery catheter with a proximal end portion, a distal end portion, and a delivery passageway extending between a proximal port along the proximal end portion and a distal port along the distal end portion; and a volume of material located within the delivery passageway; wherein the volume of material comprises a tachykinin or analog orderivative thereof; and wherein the delivery catheter is adapted to deliver the volume of tachykinin or analog or derivative thereof at least in part to the location.
- 12. The system of claim 11, wherein the delivery catheter comprises a guiding catheter.
- 13. The system of claim 12, wherein the guiding catheter comprises a coronary guiding catheter.
- 14. The system of claim 11, further comprising:
an implant; and wherein the volume of material is coupled to the implant; wherein the implant is located within the delivery catheter; and wherein the delivery catheter is adapted to deliver the implant with the volume of material at least in part to the location.
- 15. The system of claim 14, wherein the implant comprises an endolumenal stent assembly.
- 16. The system of claim 15, wherein the endolumenal stent assembly comprises:
a stent strut assembly; and a coating on the stent strut assembly; and wherein the volume of material is located within the coating.
- 17. The system of claim 15, wherein the endolumenal stent assembly is adapted to elute the volume of material into surrounding tissue over a prolonged period of time.
- 18. The system of claim 15, wherein the endolumenal stent assembly comprises an endovascular stent assembly.
- 19. The system of claim 15, wherein the tachykinin or analog or derivative thereof comprises a sialokinin or an analog or derivative thereof.
- 20. The system of claim 19, wherein the sialokinin or analog or derivative thereof comprises SK1 or an analog or derivative thereof.
- 21. The system of claim 11, wherein the material comprises a combination of SK1 and SK2 sialokinins or analogs or derivatives thereof.
- 22. The system of claim 21, wherein the ratio of SK1 to SK2 sialokinins in the material is equal to about 4:1.
- 23. The system of claim 11, wherein:
the material comprises a carrier vehicle; and the tachykinin or analog or derivative thereof has between about 1 and about 10 nanomolar concentration in the carrier vehicle.
- 24. The system of claim 11, wherein:
the material comprises a carrier vehicle; and the carrier vehicle comprises a non-sialokinin protein.
- 25. The system of claim 11, wherein the tachykinin or analog or derivative thereof is naturally occurring.
- 26. The system of claim 11, wherein the tachykinin or analog or derivative thereof is synthesized.
- 27. A method for treating an abnormal cellular proliferation condition associated with a region of tissue in a living patient, comprising:
delivering a therapeutic dose of a material to the region of tissue; inhibiting the abnormal cellular proliferation condition with the therapeutic dose of the material; and wherein the material comprises a tachykinin or an analog or derivative thereof.
- 28. The method of claim 27, further comprising:
diagnosing the region of tissue as having the abnormal cellular proliferation condition.
- 29. The method of claim 27, wherein the region of tissue comprises a tumor, and the abnormal cellular proliferation condition comprises cancer, and further wherein;
the therapeutic dose of the material is delivered to the tumor; and proliferation of the cancer is inhibited with the therapeutic dose of the material.
- 30. The method of claim 27, wherein the region of tissue comprises a wart, and further wherein:
the therapeutic dose delivery further comprises delivering the therapeutic dose to the wart; and the abnormal cellular proliferation condition inhibition further comprises inhibiting growth of the wart.
- 31. The method of claim 27, wherein:
the tachykinin being delivered comprises a sialokinin or an analog or derivative thereof.
- 32. The method of claim 31, wherein the sialokinin being delivered comprises Sk1 or an analog or derivative thereof.
- 33. The method of claim 27, wherein the material comprises a combination of SK1 and SK2 sialokinins.
- 34. The method of claim 33, wherein the ratio of SK1 and SK2 in the material is equal to about 4:1.
- 35. The method of claim 31, further comprising isolating the sialokinin from a natural source.
- 36. The method of claim 31, further comprising synthesizing the sialokinin.
- 37. The method of claim 27, wherein the therapeutic dose comprises between about 1 to about 10 nanomolar preparation of the tachykinin.
- 38. The method of claim 27, wherein the therapeutic dose comprises between about 0.5 to about 1 nanogram of tachykinin per millimeter of tissue being treated.
- 39. The method of claim 27, wherein:
the therapeutic dose comprises delivering multiple bolus volumes of the material with a frequency over a duration that comprises a period of time for treatment; and the inhibition is achieved during the period of time.
- 40. The method of claim 39, wherein the multiple bolus volumes are delivered locally into the region of tissue.
- 41. The method of claim 40, wherein the local delivery is performed via needle injection directly into the region of tissue.
- 42. The method of claim 40, wherein the bolus volumes are delivered via systemic delivery.
- 43. The method of claim 39, wherein the duration comprises more than one day.
- 44. The method of claim 43, wherein:
the duration comprises at least two days; and the frequency of bolus volume delivery is less than once daily.
- 45. The method of claim 39, wherein the multiple bolus volumes are substantially equivalent.
- 46. The method of claim 39, wherein:
the duration comprises at least about a two week period; and the therapeutic dose comprises between about 1 to about 7 nanograms of the tachykinin being delivered over the duration per milligram of the tissue being treated over the two week period.
- 47. The method of claim 39, wherein:
the therapeutic dose comprises a daily average dose of that is between about 0.25 to about 0.5 nanogram of tachykinin per milligram tissue being treated per day over the duration.
- 48. The method of claim 47, wherein the multiple bolus volumes are not delivered every day over the duration.
- 49. The method of claim 27, further comprising:
delivering the therapeutic dose into a body space wall within the body.
- 50. The method of claim 49, further comprising:
delivering the therapeutic dose into a lumenal wall of a lumen within the body.
- 51. The method of claim 50, wherein the region of tissue is located along the lumenal wall.
- 52. The method of claim 51, wherein:
the therapeutic dose delivery into the lumenal wall comprises delivering the therapeutic dose to a blood vessel wall; and the abnormal cellular proliferation condition inhibition further comprises inhibiting vascular smooth muscle cell proliferation.
- 53. The method of claim 52, further comprising:
locally delivering the therapeutic dose to the vessel wall.
- 54. The method of claim 53, further comprising:
injecting the therapeutic dose locally into the vessel wall using a local needle injection catheter.
- 55. The method of claim 54, wherein the needle of the injection catheter is coupled to an expandable balloon.
- 56. The method of claim 50, further comprising:
eluting the material from an implanted endolumenal stent located at a region along the lumen associated with the region of tissue being treated.
- 57. The method of claim 27, further comprising:
injuring the region of tissue; and delivering the material to the region of tissue after the injury.
- 58. A method for providing a therapeutic preparation of bioactive agent to treat a hyperproliferative cellular condition in a region of tissue associated with a body of a patient, comprising:
choosing a therapeutic dose of material based upon a known size of the region of tissue; and coupling the therapeutic dose of material to a delivery system that is adapted to deliver the therapeutic dose to the region of tissue; and wherein the material comprises a tachykinin.
- 59. The method of claim 58, wherein the therapeutic dose is coupled to a needle injector.
- 60. The method of claim 58, wherein the therapeutic dose is coupled to an injection catheter.
- 61. The method of claim 58, wherein the tachykinin comprises a sialokinin.
- 62. The method of claim 61, wherein the sialokinin comprises SK1.
- 63. The method of claim 61, wherein the sialokinin comprises a combination of SK1 and SK2.
- 64. The method of claim 61, wherein the relative amounts of SK1 and SK2 present in the material is equal to about a 4:1 ratio, respectively.
- 65. The method of claim 61, wherein the sialokinin is naturally occurring, and further comprising:
isolating the sialokinin from a natural source.
- 66. The method of claim 61, further comprising synthesizing the sialokinin.
- 67. The method of claim 61, further comprising preparing the therapeutic dose by combining a first tachykinin material with a second material.
- 68. The method of claim 61, wherein the therapeutic dose is chosen based upon a measured volume of the region of tissue to be treated.
- 69. The method of claim 61, wherein the region of tissue comprises a wart, and the therapeutic dose is chosen based upon a measured size of the wart.
- 70. The method of claim 61, wherein the region of tissue comprises a tumor, and the therapeutic dose is chosen based upon a measured size of the tumor.
- 71. A method for treating a wart, comprising:
delivering a therapeutic dose of material comprising tachykinin or an analog or derivative thereof to the wart.
- 72. The method of claim 71, wherein the tachykinin or analog or derivative thereof comprises a sialokinin or analog or derivative thereof.
- 73. The method of claim 72, wherein the sialokinin or analog or derivative thereof comprises SK1 or an analog or derivative thereof.
- 74. The method of claim 71, wherein the material comprises a combination of SK1 and SK2 tachykinins or respective analogs or derivatives thereof.
- 75. The method of claim 74, wherein the ratio of SK1 to SK2 present in the material is equal to about a 4:1.
- 76. The method of claim 72, further comprising isolating the sialokinin from a natural source.
- 77. The method of claim 72, further comprising synthesizing the sialokinin.
- 78. A method for treating a tumor, comprising:
delivering a therapeutic dose of material comprising tachykinin or an analog or derivative thereof to the tumor.
- 79. The method of claim 78, wherein the tachykinin or analog or derivative thereof comprises a sialokinin or an analog or derivative thereof.
- 80. The method of claim 79, wherein the sialokinin or analog or derivative thereof comprises SK1 or an analog or derivative thereof.
- 81. The method of claim 78, wherein the material comprises a combination of SK1 and SK2 tachykinins or analogs or derivatives thereof.
- 82. The method of claim 81, wherein the ratio of SK1 to SK2 present in the material is equal to about a 4:1.
- 83. The method of claim 79, further comprising isolating the sialokinin from a natural source.
- 84. The method of claim 79, further comprising synthesizing the sialokinin.
- 85. A method for providing a pharmacological preparation of sialokinins or analogs or derivatives thereof, comprising:
synthesizing at least one of SK1 and SK2 or an analog or derivative thereof in substantially pure form.
- 86. The method of claim 85, further comprising:
synthesizing both of SK1 and SK2 or their analogs or derivatives thereof; and providing the synthesized SK1 and SK2 or their respective analogs or derivatives thereof in a combination material.
- 87. The method of claim 86, further comprising:
providing the SK1 and SK2 in about a 4:1 ration in the combination material, respectively.
- 88. The method of claim 86, further comprising:
providing the combination material in a substantial powder form.
- 89. The method of claim 88, further comprising:
mixing the powder with a carrier vehicle to provide an injectable material.
- 90. The method of claim 86, further comprising sterilizing the synthesized sialokinin.
- 91. A system for treating a wall of a lumen, comprising:
an endolumenal stent that is adapted to engage the lumenal wall; and a volume of tachykinin coupled to the stent; wherein the volume of tachykinin is adapted to be delivered with a therapeutic dose into lumenal wall.
- 92. The system of claim 91, wherein the stent further comprises a stent strut and a coating on the strut, and the volume of tachykinin is located within the coating.
- 93. The system of claim 91, wherein the stent further comprises a stent strut that forms a reservoir, and the volume of tachykinin is located within the reservoir.
- 94. The system of claim 91, further comprising a cover coupled to the stent, wherein the volume of tachykinin is stored by and elutes from the cover.
- 95. The system of claim 91, wherein the tachykinin or analog or derivative thereof comprises a sialokinin or analog or derivative thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of copending application Ser. No. 10/267,918 filed on Oct. 8, 2002, incorporated herein by reference, which is a continuation of application Ser. No. 09/713,299, filed on Nov. 16, 2001, now abandoned. This application also claims priority from U.S. provisional application serial No. 60/383,499 filed on May 24, 2002, incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60383499 |
May 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09713299 |
Nov 2000 |
US |
Child |
10267918 |
Oct 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10267918 |
Oct 2002 |
US |
Child |
10445400 |
May 2003 |
US |